

These records are from CDER's historical file of information previously disclosed under the Freedom of Information Act (FOIA) for this drug approval and are being posted as is. They have not been previously posted on Drugs@FDA because of the quality (e.g., readability) of some of the records. The documents were redacted before amendments to FOIA required that the volume of redacted information be identified and/or the FOIA exemption be cited. These are the best available copies.



206 / 3

**NDA 20-613**

**Alphagan™**

**(brimonidine tartrate ophthalmic solution) 0.2% Sterile**

**Allergan**

**Volume 1 of 1**

Joanne Holmes  
phone 7-2527  
e-mail jholmesJ

NDA 20-613

Allergan, Inc.  
Attention: Adelbert L. Stagg, Ph.D.  
Director, Regulatory Affairs  
2525 Dupont Drive  
P.O. Box 19534  
Irvine, CA 92713-9534

SEP 2 1996

Dear Dr. Stagg:

Please refer to your August 31, 1995, new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Alphagan™ (brimonidine tartrate ophthalmic solution) 0.2%.

We acknowledge receipt of your amendments dated October 12 and 23, 1995, and February 26, March 1, 18, 22, and 26, April 5, 11, and 25, May 8, 10 (two), 14, 16, June 4, 12 (two), July 16, and August 28, 1996.

This new drug application provides for the indication of lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

We have completed the review of this application, including the submitted draft labeling, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the draft labeling in the submission dated August 28, 1996 with the following revision: the first sentence of the Clinical Pharmacology section should be revised into the following two sentences, "ALPHAGAN™ is an alpha adrenergic receptor agonist. It has a peak ocular hypotensive effect occurring at two hours post-dosing." Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the draft labeling submitted on August 28, 1996, as revised above. Marketing the product with FPL that is not identical to this revised draft labeling may render the product misbranded and an unapproved new drug.

Please submit sixteen copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy weight paper or similar material. For administrative purposes this submission should be designated "FINAL PRINTED LABELING" for approved NDA 20-613. Approval of this submission by FDA is not required before the labeling is used.

Should additional information relating to the safety and effectiveness of the drug become available, additional revisions of that labeling may be required.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.